SCH-442,416
SCH-442,416
Names
Preferred IUPAC name
2-(Furan-2-yl)-7-[3-(4-methoxyphenyl)propyl]-7H -pyrazolo[4,3-e ][1,2,4]triazolo[1,5-c ]pyrimidin-5-amine
Other names
SCH-442,416
Identifiers
ChEMBL
ChemSpider
UNII
InChI=1S/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)
Y Key: AEULVFLPCJOBCE-UHFFFAOYSA-N
Y InChI=1/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24)
Key: AEULVFLPCJOBCE-UHFFFAOYAA
n1n3c(nc4c(c3nc1c2occc2)cnn4CCCc5ccc(OC)cc5)N
Properties
C20 H19 N7 O2
Molar mass
389.410
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
SCH-442,416 is a highly selective adenosine A2a subtype receptor antagonist . It is widely used in its 11 C radiolabelled form to map the distribution of A2a receptors in the brain, where they are mainly found in the striatum , nucleus accumbens , and olfactory tubercle .[ 1] Given its distribution in the brain, A2a receptors have been investigated for the treatment of various neurological disorders, and SCH-442,416 has shown promise in treatment of depression ,[ 2] Parkinson's disease ,[ 3] and catalepsy .[ 4]
References
^ Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. (April 2005). "In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416". European Journal of Nuclear Medicine and Molecular Imaging . 32 (4): 405– 13. doi :10.1007/s00259-004-1688-5 . PMID 15549298 . S2CID 20909406 .
^ El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology . 61 (11 Suppl 6): S82-7. doi :10.1212/01.wnl.0000095220.87550.f6 . PMID 14663017 . S2CID 36219448 .
^ Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, et al. (March 2007). "Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model" . Journal of Pharmacological Sciences . 103 (3): 329– 32. doi :10.1254/jphs.scz070058 . PMID 17341841 .
^ Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, et al. (July 2008). "Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect" . Journal of Nuclear Medicine . 49 (7): 1183– 8. doi :10.2967/jnumed.108.051474 . PMID 18552135 .
External links